Acute erythroid leukemias have a distinct molecular hierarchy from non-erythroid acute myeloid leukemias.

In 2016 the World Health Organization (WHO) has reclassified the acute erythroid/myeloid type of acute myeloid leukemia (AML) (thereafter designated M6-AML), formerly described as M6a-AML by the French-American-British cooperative group, in either AML or myelodysplastic syndrome (MDS) depending on